Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL | OncLive Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL. @danafarber.bsky.social #leusm #hematology #oncology
www.onclive.com/view/efficac...

Orca-T Diversifies Well-Tolerated Post-Transplant Treatment Options for Hematologic Malignancies | OncLive Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field.

Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field. @huntsmancancer.bsky.social @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology
www.onclive.com/view/orca-t-...

FDA Extends Review of BLA for Orca-T in Hematologic Malignancies | OncLive The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

Following the submission of updated CMC information, the FDA has extended the review period of the BLA seeking the approval of Orca-T for the treatment of select patients with hematologic malignancies.

Read more on the new regulatory timeline #leusm #lymsm #oncology www.onclive.com/view/fda-ext...

Indirect Comparison Associates Zanubrutinib With Improved PFS in Treatment-Naive CLL | OncLive In a post hoc indirect comparison, data showed zanubrutinib was linked with improved PFS vs acalabrutinib/venetoclax in treatment-naive CLL.

In an indirect comparative analysis of the phase 3 SEQUOIA and AMPLIFY trials, zanubrutinib was associated with improved PFS vs acalabrutinib plus venetoclax in treatment-naive CLL.

Read more @fredhutch.org #leusm #oncology #OncClub www.onclive.com/view/indirec...

New TKI Formulations Engender New Horizons for CML Treatment Possibilities | OncLive Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

As newer TKIs and alternative formulations continue to emerge, CML management requires detailed attention and individualized care to navigate a growing list of options, according to Michael J. Mauro, MD, of @mskcancercenter.bsky.social. #leusm #oncology

Read more: www.onclive.com/view/new-tki...

The #EBMT26 coverage seems spotty. Can #leusm and #bmtsm communities make sure @hemedoc.bsky.social attends all conferences please? Do I need to cover his clinic or what?

@hemedoc.bsky.social, your Impact Factor is >9000 at this point

Study Finds Child-Centered Disclosure Improves Well-Being in Pediatric ALL - Oncology Nurse Advisor Semi-structured interviews with children with ALL revealed a desire for clinicians to tell them about their disease directly in age-appropriate language.

Timely, developmentally tailored diagnostic disclosure may reduce anxiety and strengthen coping among school-aged children with acute #lymphoblasticLeukemia.

https://bit.ly/3PlZRt5

#ALL #leusm

ML-Based, Treatment-Specific Risk Models Improve Prognostic Stratification in Ven-Aza–Treated AML Researchers determined a machine learning–based risk stratification approach tailored specifically to venetoclax plus azacitidine therapy improves prognostic classification for patients with newly diagnosed AML.

A machine learning–based risk stratification approach tailored specifically to venetoclax plus azacitidine therapy improves prognostic classification for patients with newly diagnosed #acuteMyeloidLeukemia. Published in @ascopost.bsky.social.

Read more here: ➡️ https://bit.ly/4sqtfNG

#AML #leusm

ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD | OncLive OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

The 2026 @ash.hematology.org Guidelines provide key recommendations on the use of pediatric-inspired regimens, the use of allo-HSCT, and the role of targeted therapies in AYA acute lymphoblastic leukemia management. @uchicagomedicine.bsky.social #leusm #oncology

www.onclive.com/view/ash-gui...

Patient Goals and Concomitant Needs Help Guide TKI Selection in CML | OncLive Jorge Cortes, MD, discusses available TKIs and how to navigate optimal treatment selection for patients with chronic myeloid leukemia.

With a plethora of TKIs approved in the CML space, Jorge Cortes, MD, explains how patient goals and concomitant medical needs help drive therapy selection and sequencing in this patient population #leusm #oncology www.onclive.com/view/patient...

🎙️On this episode of OncLive On Air, Colin Vale, MD, of @winshipcancer.emory.edu, discusses data from a trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Listen here ➡️: www.onclive.com/view/novel-t...

#leusm #hematology #oncology

Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL | OncLive Nicole Lamanna, MD, discusses the FDA approval of first-line acalabrutinib plus venetoclax for CLL and the phase 3 AMPLIFY trial data that supported it.

WATCH 👀: Nicole Lamanna, MD, of @columbiacancer.bsky.social discusses @fda.gov approval of acalabrutinib and venetoclax for CLL.

See the whole video here ➡️: www.onclive.com/view/dr-lama...

#leusm #oncology

Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL - Oncology Nurse Advisor Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

Venetoclax plus obinutuzumab yields comparable efficacy in both fit and unfit #CLL patients. 3-year PFS reached 81.9% and 75.3%, respectively (P=.09). 🧪

From @hematologyadvisor.bsky.social. Read the review: https://bit.ly/4cvVQvQ

#leusm

Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL - Oncology Nurse Advisor Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournals.hematology.org and @hematologyadvisor.bsky.social.

https://bit.ly/4cvVQvQ

#lymsm #leusm #CLL

Dr DeAngelo on Key Questions to Address in Acute Lymphoblastic Leukemia Management | OncLive Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

WATCH: Daniel J. DeAngelo, MD, PhD, of @danafarber.bsky.social, breaks down key shifts in Ph+ ALL management and persisting questions ongoing research aims to answer at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference #leusm #oncology www.onclive.com/view/dr-dean...

Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL Researchers determined venetoclax-obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated CLL.

Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournal.bsky.social.

https://bit.ly/3N3LYyQ

#CLL #leusm

ASH Releases Clinical Practice Guidelines for ALL in Adolescents and Young Adults In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.

@ash.hematology.org has released new guidelines on the treatment of adolescents and young adults with #acuteLymphoblasticLeukemia. Guidelines are available for both treatment-naïve and relapsed/refractory disease.

https://bit.ly/40tBMCP

#ALL #leusm

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD | OncLive Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Quinto Gesiotto, MD, of Tampa General Hospital, discusses TKI sequencing considerations and optimal ponatinib dosing strategies in CML management #leusm #oncology

Listen Now: www.onclive.com/view/optimiz...

BREAKING: FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL @fda.gov @danafarber.bsky.social @harvardmed.bsky.social #lymsm #leusm #hematology
www.onclive.com/view/fda-app...

WVU Cancer Institute First in the World to Treat Ultra-Rare Leukemia Using Novel Subcutaneous Immunotherapy | OncLive A WVU Cancer Institute team investigated the efficacy of subcutaneous blinatumomab in treating one of the rarest and most aggressive forms of leukemia.

WVU Cancer Institute First in the World to Treat Ultra-Rare Leukemia Using Novel Subcutaneous Immunotherapy @wvumedschool.bsky.social #leusm #hematology #oncology
www.onclive.com/view/wvu-can...

ML-NMR Analysis Displays PFS Advantage With Zanubrutinib in R/R Chronic Lymphocytic Leukemia | OncLive A ML-NMR analysis associated zanubrutinib with PFS improvements vs ibrutinib or acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

ML-NMR Analysis Displays PFS Advantage With Zanubrutinib in R/R Chronic Lymphocytic Leukemia
#leusm #oncology
www.onclive.com/view/ml-nmr-...

Medicare Advantage for People with Blood Cancers: Friend or Foe? | Podcast | ASCO Publications Dr. Chino welcomes Hari Raman, MD, MBA, author of “End-of-Life Care for Older Adults With Blood Cancers With Medicare Advantage Versus Medicare Fee-For-Service Insurance,” to discuss new research high...

Capacity for receiving appropriate #leusm #lymsm specialty cancer care is a known concern with #MedicareAdvantage plans, but paradoxically, there may be unique advantages for those at the end of life. 

🎙️I spoke to Dr Hari Raman from @danafarber.bsky.social for a new @ascocancer.bsky.social podcast

Orca-T Plus Allogeneic CAR T-Cell Therapy Signals Paradigm Shift in B-ALL | OncLive Alfonso Molina, MD, MPH, discusses a phase 1 trial evaluating Orca-T with allogeneic CAR T-cell therapy in high-risk B-cell acute lymphoblastic leukemia.

Orca-T Plus Allogeneic CAR T-Cell Therapy Signals Paradigm Shift in B-ALL @stanfordmedicine.bsky.social @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology
www.onclive.com/view/orca-t-...

Lowering Induction Daunorubicin Dosage Does Not Reduce Efficacy in Pediatric B-Cell ALL - Oncology Nurse Advisor Researchers sought to determine whether reducing the induction daunorubicin dose among pediatric patients with low-risk B-cell ALL would compromise efficacy.

Reducing the induction daunorubicin dose among pediatric patients with low-risk B-cell acute #lymphoblasticLeukemia appears to reduce toxicity without compromising efficacy. Published in @ascopost.bsky.social and @hematologyadvisor.bsky.social.

https://bit.ly/4cmwfVQ

#leusm #ALL

What is an overused oncology buzzword❓Experts at #Tandem26 weighed in with their own hot takes. 🤔

@astct.bsky.social @cibmtr.bsky.social #lymsm #leusm #melsm #oncology #hematology #AI

Check out the video here ➡️: www.onclive.com/shorts/overu...

Thanks to Dr Alfonso Molina, of @stanfordhealthcare.bsky.social, for joining us at #Tandem26 to share findings with Orca-T and allogeneic CAR-T cell therapy in B-ALL! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #leusm #hematology
www.onclive.com/conference/tct

What do you bring with you to every conference❓

Check out how experts at #Tandem26 answered. 😂

@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology

Watch the whole video here ➡️: www.onclive.com/shorts/hemat...

Cord Blood Transplantation Shows Superior Survival for MDS The uldMTX regimen may strike an optimal balance, preserving a potent graft-versus-leukemia effect while mitigating the treatment-related toxicities that can delay engraftment or increase non-relapse mortality.

Umbilical cord blood transplantation, combined with uldMTX as a GVHD prophylaxis, provides superior survival for patients with high-risk #MDS and #AML. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4k6jyR3

#leusm

Orca-T With Allogeneic CAR T-Cell Therapy Is Safe and Effective in High-Risk B-ALL
#leusm #oncology #Tandem26 @astct.bsky.social @cibmtr.bsky.social
www.onclive.com/view/orca-t-...

New publication 📝 BRUIN CLL-314 phase III results, published in the Journal of Clinical Oncology, show that pirtobrutinib demonstrated noninferior ORR to ibrutinib (87.0% vs 78.5%; p < 0.0035) in TN or R/R BTKi-naïve CLL/SLL.

Learn more: https://loom.ly/jLklx8s

#leusm #lymsm #MedNews #MedEd